IN2014CN04927A - - Google Patents

Info

Publication number
IN2014CN04927A
IN2014CN04927A IN4927CHN2014A IN2014CN04927A IN 2014CN04927 A IN2014CN04927 A IN 2014CN04927A IN 4927CHN2014 A IN4927CHN2014 A IN 4927CHN2014A IN 2014CN04927 A IN2014CN04927 A IN 2014CN04927A
Authority
IN
India
Prior art keywords
env protein
lentiviral env
mutated lentiviral
fragment
variant
Prior art date
Application number
Other languages
English (en)
Inventor
Thierry Heidmann
Original Assignee
Viroxis S A S
Centre Nat Rech Scient
Univ Paris Sud Xi
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viroxis S A S, Centre Nat Rech Scient, Univ Paris Sud Xi, Roussy Inst Gustave filed Critical Viroxis S A S
Publication of IN2014CN04927A publication Critical patent/IN2014CN04927A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN4927CHN2014 2011-12-07 2012-12-07 IN2014CN04927A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306625 2011-12-07
PCT/EP2012/074835 WO2013083799A1 (en) 2011-12-07 2012-12-07 Mutated lentiviral env proteins and their use as drugs

Publications (1)

Publication Number Publication Date
IN2014CN04927A true IN2014CN04927A (enrdf_load_stackoverflow) 2015-09-18

Family

ID=47435901

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4927CHN2014 IN2014CN04927A (enrdf_load_stackoverflow) 2011-12-07 2012-12-07

Country Status (16)

Country Link
US (1) US9682137B2 (enrdf_load_stackoverflow)
EP (1) EP2788372B1 (enrdf_load_stackoverflow)
JP (2) JP6415324B2 (enrdf_load_stackoverflow)
KR (1) KR102059918B1 (enrdf_load_stackoverflow)
CN (1) CN104169295B (enrdf_load_stackoverflow)
AU (1) AU2012350258B2 (enrdf_load_stackoverflow)
BR (1) BR112014013704B1 (enrdf_load_stackoverflow)
CA (1) CA2856180C (enrdf_load_stackoverflow)
DK (1) DK2788372T3 (enrdf_load_stackoverflow)
ES (1) ES2748864T3 (enrdf_load_stackoverflow)
IL (1) IL232926B (enrdf_load_stackoverflow)
IN (1) IN2014CN04927A (enrdf_load_stackoverflow)
MX (1) MX350689B (enrdf_load_stackoverflow)
RU (1) RU2654673C2 (enrdf_load_stackoverflow)
WO (1) WO2013083799A1 (enrdf_load_stackoverflow)
ZA (1) ZA201403617B (enrdf_load_stackoverflow)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3074088A1 (en) * 2017-09-01 2019-03-07 Inprother Aps A vaccine for use in the prophylaxis and/or treatment of a disease
AU2022208199A1 (en) 2021-01-13 2023-07-13 Centre National De La Recherche Scientifique Measles-hiv or measles-htlv vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
CA2520768A1 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
BRPI0509497B1 (pt) 2004-03-30 2022-07-19 Institut Gustave Roussy Seqüência de polipeptídeos envolvida na modulação do efeito imunosupressor de proteínas virais
ES2572132T3 (es) 2004-08-17 2016-05-30 Roussy Inst Gustave Nef del VIH mutada para modular la inmunidad
CA2735278A1 (en) 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine
RU2426788C1 (ru) * 2010-03-01 2011-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ЦНИИЭ Роспотребнадзора) Генетические конструкции для антивич-терапии

Also Published As

Publication number Publication date
JP2018150370A (ja) 2018-09-27
US20140294880A1 (en) 2014-10-02
JP6415324B2 (ja) 2018-10-31
CN104169295B (zh) 2020-07-28
KR20140116091A (ko) 2014-10-01
ES2748864T3 (es) 2020-03-18
JP2015505836A (ja) 2015-02-26
AU2012350258A1 (en) 2014-06-05
ZA201403617B (en) 2015-07-29
IL232926A0 (en) 2014-07-31
WO2013083799A1 (en) 2013-06-13
RU2014127521A (ru) 2016-02-10
EP2788372A1 (en) 2014-10-15
RU2654673C2 (ru) 2018-05-21
CN104169295A (zh) 2014-11-26
AU2012350258B2 (en) 2017-03-02
EP2788372B1 (en) 2019-07-10
BR112014013704A2 (pt) 2021-02-17
CA2856180A1 (en) 2013-06-13
MX350689B (es) 2017-09-13
KR102059918B1 (ko) 2020-02-11
US9682137B2 (en) 2017-06-20
BR112014013704B1 (pt) 2023-01-31
MX2014006744A (es) 2014-12-08
DK2788372T3 (da) 2019-10-14
AU2012350258A8 (en) 2014-07-17
IL232926B (en) 2019-01-31
CA2856180C (en) 2022-09-06

Similar Documents

Publication Publication Date Title
MY168297A (en) Cytotoxic Peptides and Antibody Drug Conjugates Thereof
NZ630542A (en) Methods of treating a tauopathy
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
EA201270722A1 (ru) Формы рифаксимина и их применение
MX359288B (es) Forma iv del clorhidrato de ivabradina.
MX2013004061A (es) Analogos de ciclosporina.
AU2013337247A8 (en) XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MY173521A (en) Trpv4 antagonists
MY168300A (en) Pharmaceutical Composition for Inhalation
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
EP2643012A4 (en) PROTEIN ADMINISTRATION FROM STEM CELL MICROVECTORS
EA201490427A1 (ru) Препарат ивабрадина или его фармацевтически приемлемых солей с замедленным высвобождением
RU2011134931A (ru) Штамм enterococcus, используемый для приготовления кисломолочных напитков
IN2014KN00892A (enrdf_load_stackoverflow)
MX2013004062A (es) Analogos de ciclosporina.
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
PH12014502876A1 (en) Pharmaceutical composition containing fimasartan and hydrochlorothiazide
BR112013017267A2 (pt) formulação de lipossomas, suspensão e composição farmacêutica
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
IN2014KN00893A (enrdf_load_stackoverflow)
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид
WO2014039074A3 (en) Therapeutic compositions and related methods
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction